- Home
- SLN vs DERM Comparison
SLN vs DERM Comparison
Compare SLN & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- DERM
- Stock Information
- Founded
- SLN 1994
- DERM 2014
- Country
- SLN United Kingdom
- DERM United States
- Employees
- SLN N/A
- DERM N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- SLN Health Care
- DERM Health Care
- Exchange
- SLN Nasdaq
- DERM Nasdaq
- Market Cap
- SLN 123.3M
- DERM 140.0M
- IPO Year
- SLN N/A
- DERM 2021
- Fundamental
- Price
- SLN $3.14
- DERM $6.25
- Analyst Decision
- SLN Buy
- DERM Strong Buy
- Analyst Count
- SLN 5
- DERM 2
- Target Price
- SLN $40.80
- DERM $10.00
- AVG Volume (30 Days)
- SLN 292.1K
- DERM 103.6K
- Earning Date
- SLN 05-15-2025
- DERM 05-12-2025
- Dividend Yield
- SLN N/A
- DERM N/A
- EPS Growth
- SLN N/A
- DERM N/A
- EPS
- SLN N/A
- DERM N/A
- Revenue
- SLN $43,258,000.00
- DERM $56,134,000.00
- Revenue This Year
- SLN N/A
- DERM $29.83
- Revenue Next Year
- SLN N/A
- DERM $54.88
- P/E Ratio
- SLN N/A
- DERM N/A
- Revenue Growth
- SLN 36.71
- DERM N/A
- 52 Week Low
- SLN $1.97
- DERM $3.20
- 52 Week High
- SLN $24.38
- DERM $7.29
- Technical
- Relative Strength Index (RSI)
- SLN 49.25
- DERM 53.65
- Support Level
- SLN $2.63
- DERM $5.98
- Resistance Level
- SLN $2.95
- DERM $6.40
- Average True Range (ATR)
- SLN 0.43
- DERM 0.62
- MACD
- SLN 0.11
- DERM -0.06
- Stochastic Oscillator
- SLN 72.67
- DERM 36.97
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.